|1.||De Clercq, Erik: 3 articles (09/2009 - 11/2002)|
|2.||Rosenkranz, Susan: 3 articles (05/2007 - 08/2002)|
|3.||De Clercq, E: 3 articles (01/2007 - 08/2001)|
|4.||Pedneault, L: 3 articles (02/2001 - 09/2000)|
|5.||Clavel, François: 2 articles (05/2008 - 02/2002)|
|6.||Para, Michael F: 2 articles (05/2007 - 08/2005)|
|7.||Yarasheski, Kevin E: 2 articles (05/2007 - 08/2005)|
|8.||Morse, Gene D: 2 articles (05/2007 - 08/2005)|
|9.||Reichman, Richard C: 2 articles (05/2007 - 08/2005)|
|10.||Adams, Elizabeth: 2 articles (05/2007 - 08/2005)|
|1.||HIV Infections (HIV Infection)
12/01/2000 - "The virological/immunological efficacy of amprenavir-containing combination regimens has been evaluated in a small number of clinical trials in patients with HIV infection. "
05/01/2011 - "Time of HIV infection, use of amprenavir and total number of PI resistance mutations were associated with having more DRV mutations."
05/01/2011 - "In the clinical model, time of HIV infection of > 10 years and use of amprenavir were independently associated with having more DRV resistance mutations. "
01/01/2001 - "Therefore, amprenavir is believed to add an important treatment option in HIV infection therapy. "
12/01/2000 - "Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection."
|2.||Acquired Immunodeficiency Syndrome (AIDS)
05/01/2007 - "A total of 82 healthy human immunodeficiency virus (HIV)-seronegative subjects were administered a single 600-mg dose of amprenavir as part of adult AIDS Clinical Trials Group protocol A5043. "
08/01/2002 - "The goal of this model-based pharmacokinetic analysis was to describe the differences observed in amprenavir pharmacokinetics among treatment arms in the Adult AIDS Clinical Trial Group (AACTG) study protocol 398 and to propose mechanisms to account for them. "
04/01/1999 - "Agenerase is the fifth drug targeting HIV's protease enzyme that has been approved to treat AIDS. "
08/01/2002 - "Amprenavir is one of six protease inhibitors presently approved for clinical use in the therapeutic treatment of AIDS. "
05/01/1999 - "Amprenavir is an oral, non-peptidic HIV-protease inhibitor undergoing phase III trials for the treatment of HIV and AIDS. "
05/01/2000 - "Site-directed mutagenesis studies confirmed the causal role of N88S in determining amprenavir hypersensitivity. "
04/01/2006 - "However, cutaneous hypersensitivity reactions to amprenavir occur in up to 28% of patients, with treatment discontinuation required in 3% of cases. "
05/01/2000 - "Amprenavir should be avoided in patients with a known sulfonamide allergy. "
05/01/2000 - "A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir."
05/01/2000 - "The presence of the N88S mutation and associated amprenavir hypersensitivity may be useful in predicting an improved clinical response to amprenavir salvage therapy."
|4.||Body Weight (Weight, Body)
05/01/2007 - "Amprenavir had a mean total clearance of 1.163 liters/h/kg of body weight (0.7), a central volume of distribution of 1.208 liters/kg (0.8), a peripheral volume of distribution of 8.2 liters/kg (0.81), and distributional clearance of 0.04 liters/h/kg (0.81). "
01/01/2005 - "The doses of amprenavir evaluated, 5, 10, 15, and 20 mg/kg of body weight, were comparable to those evaluated in adult phase I and II studies. "
01/01/2005 - "The most common clinical adverse event associated with amprenavir, administered as soft gelatin capsules, was nausea. "
07/01/1999 - "The most common adverse events related to amprenavir were headache, nausea, and hypesthesia. "
01/01/1999 - "Common side effects of amprenavir include nausea, vomiting, diarrhea, and numbness and tingling around the mouth."
09/01/2000 - "A significantly greater incidence of drug-related nausea, vomiting, rash and oral/perioral paresthesia was observed with amprenavir/lamivudine/zidovudine than with lamivudine/zidovudine. "
|2.||Protease Inhibitors (Protease Inhibitor)
|8.||HIV Protease Inhibitors
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Highly Active Antiretroviral Therapy (HAART)